Publication date: Aug 08, 2019
Background and Aims: It is not known whether inflammatory bowel disease (IBD) enhances the risk of Parkinson’s disease (PD) or whether PD diagnosis is the result of increased health care use. We determined the risk of developing PD among patients with IBD in terms of health care and medication use. Methods: A nationwide population-based study was conducted using claims data from the Korean National Health care Insurance service. From 2010 to 2013, patients with Crohn’s disease (CD) and ulcerative colitis (UC) were identified through both International Classification of Disease, Tenth Revision (ICD-10) and national rare intractable disease (RID) registration program codes. We compared 38,861 IBD patients with age and sex-matched non-IBD individuals at a ratio of 1:3. Patients with newly diagnosed PD were identified through both ICD-10 and RID codes. Results: The incidence of PD among patients with IBD was 49 per 100,000 person-years. The risk of developing PD in patients with IBD was significantly higher than controls even after adjustment for health care use (adjusted hazard ratio (aHR), 1.87; P
Park, S., Kim, J., Chun, J., Han, K., Soh, H., Kang, E.A., Lee, H.J., Im, J.P., and Kim, J.S. Patients with Inflammatory Bowel Disease Are at an Increased Risk of Parkinson’s Disease: A South Korean Nationwide Population-Based Study. 21897. 2019 J Clin Med (8):8.
|disease||DOID||Inflammatory Bowel Disease|
|disease||MESH||Inflammatory Bowel Disease|
- The Incidence Rates and Risk Factors of Parkinson’s Disease in Patients with Psoriasis: A Nationwide Population-based Cohort Study.
- Effect of polygenic load on striatal dopaminergic deterioration in Parkinson disease.
- White matter hyperintensities as a predictor of freezing of gait in Parkinson’s disease.
- Quantitative analysis of nasal transcripts reveals potential biomarkers for Parkinson’s disease.
- “Depressed” caudate and ventral striatum dopamine transporter availability in de novo Depressed Parkinson’s disease.
- Striatal dopamine activity and myocardial I-metaiodobenzylguanidine uptake in early Parkinson’s disease.